University of Oklahoma

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Oklahoma sits in the top decile of US sponsors by registered trial count (#100 of 15,742 sponsors by registered trial count).

358 total trials 80 currently recruiting 196 completed early-phase tilt top decile by trial count

University of Oklahoma: 358 sponsored US clinical trials, 80 recruiting.

University of Oklahoma sponsors 358 registered US clinical trials on ClinicalTrials.gov, 80 of them currently recruiting, and 196 completed. 26 of these trials are in Phase 3-4 (later-stage) and 88 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 6 trials.

Top-decile sponsor footprint

University of Oklahoma ranks in the top decile of sponsors by registered trial count (#100 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

196 of 240 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

358 total, page 7 of 8

COMPLETED

Temperature Changes During Induction of General Anesthesia in Pediatric Patients

NCT00710320
COMPLETED Early Phase 1

Balance in Children With Cochlear Implants

NCT00642343
COMPLETED NA

Addition of Nitrous Oxide and Its Effects on Depth of Anesthesia

NCT00717574
COMPLETED

A Study of Cytokine and Inflammatory Markers in Patients With Chronic Renal Failure

NCT00565994
COMPLETED NA

Local Anesthesia and Pain Perception During an Amniocentesis

NCT00583011
COMPLETED Phase 3

A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

NCT00541346
COMPLETED

Intraoperative M-Entropy Measurements

NCT00599066
COMPLETED Phase 2

Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer

NCT00542490
COMPLETED Phase 2

Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer

NCT00511992
COMPLETED NA

Warming Mattress Versus Polyethylene Wrapping to Prevent Hypothermia in Preterm Newborns.

NCT00603837
COMPLETED

How do Attitude About Pay for Performance Differ Among Different Anesthesia Care Provider and Over Time

NCT01116960
COMPLETED NA

Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant

NCT00466518
COMPLETED NA

Development of Education Materials for Prevention of FAS in Russia

NCT01971398
TERMINATED Phase 4

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

NCT00420355
COMPLETED NA

The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

NCT00644657
TERMINATED NA

Effects of Shrinker Use on Healing and Volume

NCT00693628
TERMINATED NA

Glucose Control In Hematopoetic Stem Cell Transplant

NCT00582036
TERMINATED NA

Study of Acamprosate in Driving Under the Influence (DUI) Court Participants

NCT00425711
COMPLETED NA

Evaluation of Upper Extremity Prosthesis

NCT00584103
COMPLETED

Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation

NCT00584922
COMPLETED NA

Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)

NCT00561223
COMPLETED NA

Comparing IM vs. Vaginal Progesterone for Pre-term Birth

NCT00579553
COMPLETED NA

Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients

NCT00671723
COMPLETED NA

Trial of Immediate vs. Delayed Cord Clamping in the Preterm Neonate

NCT00579839
COMPLETED NA

Home-based vs. Supervised Exercise for People With Claudication

NCT00618670
COMPLETED Phase 1

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

NCT00453050
COMPLETED NA

Depth of Anesthesia on Implicit Memory

NCT00584324
COMPLETED NA

Autoimmune Dysregulation in Pigmentary Glaucoma

NCT00280345
COMPLETED

Phacoemulsification Sleeves

NCT00289068
TERMINATED Phase 2

Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

NCT00582205
COMPLETED NA

Triamcinolone vs. Laser for Diabetic Macular Edema

NCT00229931
COMPLETED Phase 1

A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis

NCT00584597
COMPLETED Phase 3

Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD

NCT00418262
COMPLETED Phase 1

Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD

NCT00417794
COMPLETED Phase 2

Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

NCT00222469
COMPLETED Phase 1

Using Dexamethasone After Uvulopalatopharyngoplasty

NCT00584168
COMPLETED NA

Fluoroscopy Guided Femoral Arterial Access

NCT00222430
COMPLETED Phase 1

Comparing Over-the-counter Dry Mouth Remedies After Radiation

NCT00595933
COMPLETED Phase 2

Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus

NCT00237640
COMPLETED NA

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases

NCT00582894
COMPLETED NA

Osteopathic Manipulative Treatment and Its Relationship to Autonomic Nervous System Activity

NCT00516984
COMPLETED Phase 1

Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy

NCT00222443
TERMINATED Phase 4

Effects of Naproxen on Physical Performance

NCT00410995
TERMINATED NA

Ablation of Inappropriate Sinus Tachycardia

NCT00584649
COMPLETED NA

AV Nodal Reentrant Tachycardia Study

NCT00618683
COMPLETED Phase 4

Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease

NCT00229528
COMPLETED NA

Navi-Star Thermo-Cool Catheter For Ablation of Atrial Fibrillation

NCT00584415
COMPLETED

A Retrospective Review of Malignant Liver Tumors

NCT00728650
COMPLETED NA

Effectiveness Trial for Project SafeCare for Child Neglect

NCT01391754
COMPLETED Phase 4

Management of Superficial Thrombophlebitis

NCT00264381
← Previous Page 7 of 8 Next →

Phase Distribution

PhaseTrial count
Phase 1 48
Phase 2 40
Phase 3 8
Phase 4 18

Therapeutic Areas

Prostate Cancer 6
Smoking Cessation 5
Health Behavior 4
Peripheral Artery Disease 4
Substance Use Disorders 4
Claudication 3
Cigarette Smoking 3
Tobacco Use 3
Atrial Fibrillation 3
Endometrial Cancer 3

What is open in the University of Oklahoma pipeline

80 recruiting of 358 indexed (22% open); 196 completed (55%).

Phase mix: 26 late (III/IV) vs 88 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Oklahoma: open-pipeline peers nationwide

Peers matched on 358 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

University of Oklahoma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%5%10%15%20%25% Total trials Recruiting share University of OklahomaNew York State Psychiatric InstituteRoswell Park Cancer InstituteUNC Lineberger Comprehensive Cancer CenterUniversity of ArizonaALX OncologyBiosense WebsterEnglewood Hospital and Medical CenterEnsysce Biosciences
University of Oklahoma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Oklahoma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 358 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Oklahoma page

358 registered trials is a research-attention snapshot, not an endorsement of University of Oklahoma or any single study.

  • 80 of University of Oklahoma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition University of Oklahoma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Oklahoma pipeline card: 358 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.